"Bruker is very well positioned to capitalize on strong demand tailwinds from a number of important secular trends, including accelerating shifts to post-genomic research and epigenetics, functional and imaging proteomics, structural biology, biologic drugs, a paradigm shift in clinical microbiology, protein and metabolite molecular diagnostics, fast and quantitative microscopy, 450 mm semiconductor FABs, shrinking semicon and nanotech feature sizes, and further adoption of superconductivity-enabled products in research, healthcare and energy/grid applications."
The following was also copied from Bruker's 4Q'11 press release.
"For the fourth quarter of 2011, Bruker’s cash flow from operations was $92.1 million, and free cash flow was $76.1 million. As of December 31, 2011, Bruker had cash, cash equivalents and restricted cash of $248.2 million and net debt of $54.9 million. As of December 31, 2011, Bruker’s Intangible Asset Ratio (IAR) was 13.8% and total debt leverage ratio was 1.2x."
~48% of BRKR shares are closely held. And, according to Bruker's "Key Statistics" page on Finance.Yahoo.com, institutions and mutual funds own 99% of BRKR's float.
Yesterday (02012.02.21) BRKR closed at $15.79. 52-week range: $11.48 - $21.65. BRKR was #8 in the GDT::Portfolio when the markets closed yesterday.
No comments:
Post a Comment